Study investigating the pharmacokinetic interaction between theophylline and roflumilast in healthy adults

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 7, 2011, Pages 451-460

  Bohmer G ^a   Gleiter, C H ^a   Hunnemeyer A ^b   Lahu, G ^b   Bethke, T D ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Nycomed GmbH   (Germany)

Author keywords

CYP1A2; Human; Interaction; Roflumilast; Theophylline

Indexed keywords

HEPARIN; PARACETAMOL; ROFLUMILAST; THEOPHYLLINE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BIOEQUIVALENCE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EVENING DOSAGE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INSOMNIA; LABORATORY TEST; LIMB PAIN; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MYALGIA; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TREMOR; VOMITING;

ADOLESCENT; ADULT; AMINOPYRIDINES; AREA UNDER CURVE; BENZAMIDES; BLOOD PRESSURE; BODY TEMPERATURE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; CYCLOPROPANES; CYTOCHROME P-450 CYP1A2; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; QUALITY CONTROL; THEOPHYLLINE; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 79960170105     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201535     Document Type: Article

References (31)

1. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374: 685-694. doi:10. 1016/S0140-6736(09)61255-1 PubMed
2. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374: 695-703. doi:10.1016/S0140-6736(09)61252-6 PubMed
3. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001; 297: 267-279. PubMed
4. Bethke TD, Böhmer GM, Hermann R, Hauns B, Fux R, Mörike K, David M, Knoerzer D, Wurst W, Gleiter CH. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol. 2007; 47: 26-36. doi:10.1177/0091270006294529 PubMed
5. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 2001; 297: 280-290. PubMed
6. Hermann R, Nassr N, Lahu G, Péterfai E, Knoerzer D, Herzog R, Zech K, de Mey C. Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis. Clin Pharmacokinet. 2007; 46: 403-416. PubMed doi:10.2165/00003088-20074605000003
7. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med. 2003; 167: 813-818. doi:10.1164/rccm.200210-1142PP PubMed
8. European Medicines Agency. Guideline on the investigation of drug interactions (CPMP/EWP/560/95/Rev. 1 - Corr.*). London; 2010.
9. Stockley I. Stockley's drug interactions. London: Pharmaceutical Press; 2010.
10. Tröger U, Meyer FP. Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation. Clin Pharmacokinet. 1995; 28: 287-314. doi:10.21 65/00003088-199528040-00003 PubMed
11. Ram FS, Jardin JR, Atallah A, Castro AA, Mazzini R, Goldstein R, Lacasse Y, Cendon S. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med. 2005; 99: 135-144. doi:10.1016/j.rmed.2004.10.009 PubMed
12. Skinner MH. Adverse reactions and interactions with theophylline. Drug Saf. 1990; 5: 275-285. doi:10.2165/00002018-199005040-00004 PubMed
13. Yoshikawa H. First-line therapy for theophylline-associated seizures. Acta Neurol Scand. 2007; 115 (Suppl): 57-61. doi:10.1111/j.1600-0404.2007.00810. x PubMed (Pubitemid 46376172)
14. Bauer L.A. Applied clinical pharmacokinetics. New York: McGraw-Hill; 2008.
15. Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med. 1996; 334: 1380-1388. doi: 10.1056/NEJM199605233342107 PubMed
16. Molfino NA, Zhang P. A meta-analysis on the efficacy of oral theophylline in patients with stable COPD. Int J Chron Obstruct Pulmon Dis. 2006; 1: 261-266. doi:10.2147/copd.2006.1.3.261 Pub Med
17. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD. Gig Harbor WA: Medical Communications Resources Inc.; 2009.
18. Miravitlles M, Murio C, Tirado-Conde G, Levy G, Muellerova H, Soriano JB, Ramirez-Venegas A, Ko FW, Canelos-Estrella B, Giugno E, Bergna M, Chérrez I, Anzueto A. Geographic differences in clinical characteristics and management of COPD: the EPOCA study. Int J Chron Obstruct Pulmon Dis. 2008; 3: 803-814. PubMed
19. Hauschke D, Steinijans V, Pigeot I. Bioequivalence studies in drug development. Methods and applications. Chichester: John Wiley & Sons; 2007. p. 30-33.
20. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15: 657-680. doi:10.1007/BF01068419 PubMed
21. Steinijans VW, Hartmann M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol. 1991; 29: 323-328. PubMed
22. Lahu G, Nassr N, Herzog R, Elmlinger M, Ruth P, Hinder M and Huennemeyer A. Effect of steadystate enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharm. 2010; [Epub ahead of print].
23. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1/ Corr.**). London; 2010.
24. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol. 2005; 97: 125-134. doi:10.1111/j.1742-7843.2005.pto-973160.x PubMed
25. Nycomed. Data on file.
26. Murdoch RD, Zussman B, Schofield JP, Webber DM. Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers. J Clin Pharmacol. 2004; 44: 1046-1053. doi: 10.1177/0091270004266488 PubMed (Pubitemid 39096819)
27. Gross NJ, Giembycz MA, Rennard SI. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. COPD. 2010; 7: 141-153. doi:10.3109/15412551003758304 PubMed
28. Summary of Product Characteristics (UK). DAXAS® 500 micrograms film-coated tablets (Merck Sharp & Dohme Ltd, UK) http://www.medicines.org. uk. Accessed January 25, 2010.
29. Lahu G, Huennemeyer A, Herzog R, McCracken N, Hermann R, Elmlinger M, Zech K. Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide. Int J Clin Pharmacol Ther. 2009; 47: 236-245. PubMed
30. Lahu G, Huennemeyer A, von Richter O, Hermann R, Herzog R, McCracken N, Zech K. Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol. 2008; 48: 1339-1349. doi:10.1177/0091270008321941 PubMed
31. Nassr N, Lahu G, von Richter O, Reutter F, Knoerzer D, Zech K, Erb KA, Schug B, Blume H, Hermann R. Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects. Br J Clin Pharmacol. 2007; 63: 365-370. doi:10.1111/j.1365-2125.2006.02762.x PubMed